Aligned Genetics얼라인드
238120 · KOSDAQ · ₩238120 · 얼라인드
- Market cap
- ₩35B
- Enterprise value
- ₩35B
- P/E
- 7.5×
- P/B
- 0.9×
- Dividend yield
- 0.0%
- ROE
- 11.8%
- Net margin
- 28.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−59.8% from the high
₩2,345Today: ₩2,410 – ₩2,525₩6,050
Returns
- 1W−4.3%
- 1M−17.9%
- 3M−12.7%
- 6M−44.7%
- YTD−37.1%
- 1Y−25.2%
- Volume today
- 17,295
- 1.0× the 20-day average
- Traded today
- ₩42M
- Listed shares
- 14,218,274
- EPS (12 months)
- ₩326
- Earnings yield 13.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumWeak-15.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Aligned Genetics stock overview
Aligned Genetics (얼라인드, KRX: 238120) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops and manufactures life science research and diagnostic instruments and reagents, and sells them worldwide as a technology venture. Its shares closed at ₩2,435 on Oct 27, 2026, down 3.56% on the day, giving it a market value of ₩35B.
Key facts
- Market cap
- ₩35B
- Sector
- Medical & precision devices
- Latest price change
- −3.56%
- As of
- Oct 27, 2026
- Main business
- The company develops and manufactures life science research and diagnostic instruments and reagents, and sells them worldwide as a technology venture.
Quick answers about Aligned Genetics
- What does Aligned Genetics do?
- The company develops and manufactures life science research and diagnostic instruments and reagents, and sells them worldwide as a technology venture. Its main product lines are automated cell counting systems for labs in research, cell therapy, food, healthcare and infectious disease diagnostics, tissue clearing and 3D imaging systems (including the X-CLARITY tissue clearing device), and digital cell imaging systems (such as CELENA) that replace conventional analog fluorescence microscopes. Its products are sold to research institutes, academia and industry across the world, with the company making the parts needed for each tissue-clearing step in-house.
- What is the market cap of Aligned Genetics?
- The market capitalisation of Aligned Genetics was ₩35B at the close on Oct 27, 2026.
- Who are the largest shareholders of Aligned Genetics?
- According to the latest official filings, the largest reported holders are Jeong Yeon-cheol (39.78%, as of Apr 4, 2025); Jeong Yeon-seok (1.89%, as of Jun 26, 2026).
- When is the next earnings report from Aligned Genetics?
- Korean companies rarely announce results dates in advance. Based on when Aligned Genetics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops and manufactures life science research and diagnostic instruments and reagents, and sells them worldwide as a technology venture. Its main product lines are automated cell counting systems for labs in research, cell therapy, food, healthcare and infectious disease diagnostics, tissue clearing and 3D imaging systems (including the X-CLARITY tissue clearing device), and digital cell imaging systems (such as CELENA) that replace conventional analog fluorescence microscopes. Its products are sold to research institutes, academia and industry across the world, with the company making the parts needed for each tissue-clearing step in-house.
Written by AI from the company's latest annual report.
- Korean name
- 얼라인드
- Themes
- Medical devices
- CEO
- 정연철
- Founded
- Oct 2008
- Listed
- Nov 2016
- Listed shares
- 14,218,274
- Fiscal year ends
- Month 12
- Website
- www.alignedgenetics.co.kr
Similar companies
- TSE131290 · ₩2.9T₩260,000+7.88%
- Kctech281820 · ₩1.8T₩91,900+6.37%
- Classys214150 · ₩1.7T₩26,500−2.57%
- Park Systems140860 · ₩1.6T₩225,500+1.12%
- Curiox Biosystems445680 · ₩1.1T₩62,300+6.13%
- DI003160 · ₩1.1T₩37,800+4.71%
- Seers458870 · ₩1T₩26,300−5.57%
- LivsMed491000 · ₩937B₩37,100+1.50%
Recent filings
See all- Report on Results of Disposal of Treasury SharesSep 3, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended: Treasury share sale decisionJun 30, 2026
- Insider shareholding reportJun 26, 2026
- Share cancellation decisionMay 29, 2026
Titles in Korean until English translations are added.
Also known as: Aligned Genetics / 얼라인드 / 238120 / KRX:238120
Source: KRX statistical information